Last updated: 2026-09-16 07:34:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Kenvue Inc. (KVUE) operates in the PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $17.91, with a market capitalisation of $34.40B and a P/E ratio of 20.76. Over the past 52 weeks, its price has ranged from $14.02 to $20.13. This page covers its latest market performance, valuation, price trends and company information.
$34.40B | |
$17.93 | |
$27.80 | |
$14.02 | |
$17.91 | |
50.03M | |
22.81M | |
20.76 | |
$20.13 | |
$14.02 | |
4.63% | |
-- |
Kenvue Inc. (KVUE) last closed at $17.91 as of 2026-09-15 23:31:00, unchanged from the previous close of $17.91.
During the latest regular trading session, KVUE traded between $14.02 and $27.80, with a volume of 50.03M shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Kenvue Inc. (KVUE) moved from $18.74 to $17.91, representing a decline of 4.42% ($0.83).
The stock traded between $17.60 and $18.98 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 39.08 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 63.7%
KVUE is currently trading at $17.91, placing it 63.7% of the way from its 52-week low of $14.02 to its 52-week high of $20.13. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.
| Industry | PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS |
| Employees | 22000 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Kenvue Inc. (KVUE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.